HCPCS G9825: Her-2/neu Negative or Undocumented/Unknown

HCPCS Level II code G9825 denotes a HER2/neu status of negative or undocumented/unknown. This code is used in pathology and laboratory reporting to indicate either a confirmed negative HER2 result or absence of documented test results. Accurate coding of HER2 status affects clinical decision-making for targeted therapies and supports appropriate documentation for quality measurement and coverage determinations.

Key payers considered in national coverage contexts include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for HER2 status reporting, typical sites of service, and the role of this code in claims submissions. The publication outlines benchmarks and coverage considerations where available, highlights policy updates relevant to biomarker documentation, and explains how this code fits within pathology and oncology service lines.

This summary is intended for national audiences involved in coding, billing, and clinical documentation, offering clarity on what G9825 represents, why it matters for treatment pathways and quality reporting, and what practitioners and administrators should expect when encountering this code on service lines. Data not available in the input will be noted where applicable.

Billing Code Overview

HCPCS Level II code G9825 indicates Her-2/neu negative or undocumented/unknown. This code is used to report the HER2 (human epidermal growth factor receptor 2) testing status when results are negative or when documentation of HER2 status is not available.

Service type: Biomarker status reporting related to breast cancer pathology testing
Typical site of service: Pathology and laboratory reporting associated with outpatient or hospital-based specimen analysis

Clinical Context

A typical patient is a 55-year-old woman with newly diagnosed invasive breast carcinoma undergoing pathological assessment to determine HER2 status for treatment planning. The tumor sample (core biopsy or surgical specimen) is submitted to the pathology laboratory for immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) testing. The ordering clinician (medical oncologist or surgeon) needs a definitive HER2 result to guide use of HER2-targeted therapies. The laboratory documents HER2 as negative or reports HER2 status as undocumented/unknown when testing is not performed or results are inconclusive. Specimen handling, IHC staining, score interpretation, and reflex FISH testing when IHC is equivocal are part of the clinical workflow. Results are reported in the pathology report and communicated to the treating clinician for staging and therapeutic decision-making.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when work required is substantially greater than usually required.
`23`	Unusual anesthesia	Use when general anesthesia is medically necessary for a procedure normally performed with local anesthesia.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Anatomic Pathology	Primary specialty performing HER2 testing and interpretation.
`2085R0201X`	Hematopathology	Pathologists with expertise in tumor marker testing and FISH interpretation.
`208000000X`	Surgical Pathology	Surgical pathologists who handle breast surgical specimens and tissue processing.
`363A00000X`	Medical Oncology	Orders and uses results for systemic therapy planning.
`207L00000X`	Clinical Laboratory	Laboratory directors and personnel performing IHC/FISH assays.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C50.912`	Malignant neoplasm of unspecified site of right female breast	Primary diagnosis for invasive breast cancer where HER2 testing is performed.
`C50.911`	Malignant neoplasm of unspecified site of left female breast	Primary diagnosis for invasive breast cancer where HER2 testing is performed.
`D05.90`	Unspecified benign mammary dysplasia of unspecified breast	Benign lesions may prompt receptor testing in certain clinical contexts.
`C79.81`	Secondary malignant neoplasm of breast	Metastatic disease involving breast tissue where HER2 status may guide systemic therapy.
`Z85.3`	Personal history of malignant neoplasm of breast	Relevant for recurrent disease evaluation and HER2 reassessment.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`88342`	Immunohistochemistry, per specimen; initial single antibody stain	Commonly used for HER2 IHC testing on breast tumor tissue.
`88360`	Morphometric analysis; tumor immunohistochemistry quantitative evaluation	Used when quantitative assessment of IHC staining intensity is performed.
`88365`	Consultation and review, pathology (secondary review)	Used when a second pathologist provides diagnostic consultation on HER2 interpretation.
`88367`	Morphometric analysis by computer-assisted image analysis	Used for computer-assisted scoring of HER2 IHC when available.
`88377`	In situ hybridization (e.g., FISH), each probe; manual	Used for HER2 gene amplification testing when IHC is equivocal or requires confirmation.

OpenPayer

Summary & Overview